Literature DB >> 17996585

Molecular pathogenesis of multiple myeloma.

Giovanni Tonon1.   

Abstract

Several genetic mechanisms underlying the pathogenesis of multiple myeloma have been elucidated in the past decade. In particular, the presence of two distinct karyotypic patterns, that identify two patient groups and drive different pathogenetic and prognostic paths in the development of myeloma, have been identified, and the role of reciprocal chromosomal translocations and cyclin dysregulation have been identified. Despite this progress, several questions of critical importance remain to be addressed for the understanding of the pathogenesis of multiple myeloma. For example, little is known about the role of th primary events, including cyclin D overexpression and multiple myeloma set domain activity in the early pathogenesis of the disease. The additional lesions that promote the evolution of monoclonal gammopathy of undetermined significance to multiple myeloma (MM) and, within MM, the progression toward a more aggressive and proliferative disease is only starting to emerge. The heterotypic relationship between the stroma and the MM plasma cells also has not been fully explored. The understanding of the biology of MM cancer stem cells and of the pathways driving their maintenance, proliferation, and differentiation is still in its infancy. Recent and ongoing high-resolution genomic studies are leading the way toward a more refined and conclusive understanding of this disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17996585     DOI: 10.1016/j.hoc.2007.08.004

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  5 in total

1.  Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma.

Authors:  Isabella C Glitza; Gary Lu; Rupin Shah; Qaiser Bashir; Nina Shah; Richard E Champlin; Jatin Shah; Robert Z Orlowski; Muzaffar H Qazilbash
Journal:  Leuk Lymphoma       Date:  2014-08-18

2.  Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2.

Authors:  Bonnie K Arendt; Marina Ramirez-Alvarado; Laura A Sikkink; Jonathan J Keats; Gregory J Ahmann; Angela Dispenzieri; Rafael Fonseca; Rhett P Ketterling; Ryan A Knudson; Erin M Mulvihill; Renee C Tschumper; Xiaosheng Wu; Steven R Zeldenrust; Diane F Jelinek
Journal:  Blood       Date:  2008-06-20       Impact factor: 22.113

3.  TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity.

Authors:  Moshe E Gatt; Kohichi Takada; Mala Mani; Mikael Lerner; Marjorie Pick; Teru Hideshima; Daniel E Carrasco; Alexei Protopopov; Elena Ivanova; Olle Sangfelt; Dan Grandér; Bart Barlogie; John D Shaughnessy; Kenneth C Anderson; Daniel R Carrasco
Journal:  Br J Haematol       Date:  2013-05-07       Impact factor: 6.998

4.  Conventional and molecular cytogenetic analyses in Turkish patients with multiple myeloma.

Authors:  Beyhan Aras Durak; Olga Meltem Akay; Gülçin Sungar; Güney Bademci; Vahap Aslan; Jülide Caferler; Muhsin Ozdemir; Oğuz Cilingir; Sevilhan Artan; Zafer Gülbaş
Journal:  Turk J Haematol       Date:  2012-06-15       Impact factor: 1.831

5.  Identification of novel pathogenic copy number aberrations in multiple myeloma: the Malaysian context.

Authors:  Pau Ni Ivyna Bong; Ching Ching Ng; Kah Yuen Lam; Puteri Jamilatul Noor Megat Baharuddin; Kian Meng Chang; Zubaidah Zakaria
Journal:  Mol Cytogenet       Date:  2014-04-01       Impact factor: 2.009

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.